Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SGK1 | O00141 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8170852 | 0.85 | CYP2C9 (0.41) | CYP2C9KAT6AKDM4ECYP1A2KMT2A | |
| SCHEMBL27902050 | 0.81 | CYP2C9 (0.47) | CYP2C9CYP1A2 | |
| SCHEMBL6817227 | 0.81 | CYP2C9 (0.32) | CYP2C9EPHX2KMT2ANCOA3 | |
| SCHEMBL6068742 | 0.80 | CYP1A2 (0.45) | CYP2C9CYP1A2 | |
| Hydrochloric Acid SCHEMBL27783235 | 0.78 | CYP1A2 (0.44) | CYP2C9CYP1A2 | |
| Phosphoric Acid SCHEMBL28832745 | 0.78 | CYP1A2 (0.40) | CYP2C9CYP1A2 | |
| SCHEMBL335422 | 0.78 | CYP1A2 (0.59) | CYP2C9EPHX2CYP1A2KMT2ALMNA | |
| SCHEMBL31278334 | 0.78 | CYP1A2 (0.59) | CYP2C9EPHX2CYP1A2KMT2ALMNA | |
| SCHEMBL1374190 | 0.75 | CYP1A2 (0.39) | CYP2C9CYP1A2 | |
| Diethyl Hydrogen Phosphate SCHEMBL27840807 | 0.74 | CYP1A2 (0.35) | CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6015828-A | ADMINISTERING CONDENSATION AGENT AND AMINE; DEACTIVATING AND NEUTRALIZING CHARGED AMINO ACID RESIDUES OF CHANNELS | CUPPOLETTI JOHN (US) | 2000-01-18 | — | — | US | claimed |
| CN-101171042-B | Coating the whole surface of a built-in prothesis and coated built-in prothes | HEMOTEQ AG | 2012-01-18 | — | — | CN | disclosed |
| CN-102258811-A | Manufacture, method and use of active substance-releasing medical products for permanently keeping blood vessels open | — | 2011-11-30 | — | — | CN | disclosed |
| CN-101972492-A | Medical product for curing body channel narrow and preventing dangerous restenosis | HEMOTEQ AG | 2011-02-16 | — | — | CN | disclosed |
| CN-101687066-A | Medical product for treating stenosis of body passageways and preventing dangerous restenosis | HEMOTEQ AG | 2010-03-31 | — | — | CN | disclosed |
| CN-101583384-A | Manufacture, method and use of active-releasing medical products for permanent vascular patency | HEMOTEQ AG (DE) | 2009-11-18 | — | — | CN | disclosed |
| CN-101171042-A | A method for coating the whole surface of a built-in prothesis | HEMOTEQ GMBH (DE) | 2008-04-30 | — | — | CN | disclosed |
| WO-2004009584-A1 | NOVEL P-GLYCOPROTEIN INHIBITOR, METHOD FOR PREPARING SAME AND ORAL COMPOSITION COMPRISING SAME | HANMI PHARM. CO., LTD. (KR) | 2004-01-29 | — | — | WO | disclosed |
| US-5432202-A | Regulating potassium transport across cellular membranes | NEW YORK UNIVERSITY (US) | 1995-07-11 | — | — | US | disclosed |
| EP-0597830-A1 | USE OF POLYAMINES AS IONIC-CHANNEL REGULATING AGENTS | NEW YORK UNIVERSITY NYU MEDICAL CENTER (US) | 1994-05-25 | — | — | EP | disclosed |
| US-5242947-A | Use of polyamines as ionic-channel regulating agents | NEW YORK UNIVERSITY (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0597830-A4 | USE OF POLYAMINES AS IONIC-CHANNEL REGULATING AGENTS. | NEW YORK UNIVERSITY NYU MEDICA (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1991000853-A1 | USE OF POLYAMINES AS IONIC-CHANNEL REGULATING AGENTS | NEW YORK UNIVERSITY (US) | 1991-01-24 | — | — | WO | disclosed |